Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Lucy Norris

SENIOR EXP OFFICER OBS&GYN (P/T 17/8/06) (Obstetrics)
COOMBE WOMENS HOSPITAL
      
Profile Photo

Dr. Lucy Norris

SENIOR EXP OFFICER OBS&GYN (P/T 17/8/06) (Obstetrics)
COOMBE WOMENS HOSPITAL

 lnorris@tcd.ie

 3531896 2116


Lucy Norris MSc Mol. Med. PhD https://orcid.org/0000-0001-7862-3230. Lucy Norris graduated from Trinity College Dublin with an honours degree in Biochemistry. She was awarded a PhD in 1992 from TCD Dept of Obstetrics and Gynaecology based on her work investigating platelet activation in pregnancy, pre-eclampsia and oral contraception. She is the Principal Investigator of Coagulation Research group at the Department of obstetrics and Gynaecology and has over 25 years' experience in the area of haemostasis and thrombosis research. Her current research program focuses on the prediction of venous thrombosis in gynaecological cancer and the role of coagulation gene expression in the aetiology of ovarian cancer and has received independent funding from the HRB and the pharmaceutical industry. She has over 100 peer reviewed articles many as senior author(h-index:24, i10 index 41, Citations 2188). She is co-editor in chief of the journal "Thrombosis Update" and a member of the editorial board of Thrombosis Research and European Journal of Gynaecological Oncology.
  Biomedical sciences   Cardiovascular risk assessment and hormone replacement therapy   Clinical research, trials   Coagulation biochemistry and disorders   Cytokines, Nitric Oxide   Foetal, maternal and neonatal physiology   Haemotology   Hormone physiology and biochemistry   Inflammation and coagulation syndromes   Medical Sciences, Research   Menopause   Molecular haematology   Oral contaraceptives and haemostasis   Pre-eclampsia and intrauterine growth retardation   Prevention, treatment of thromboembolic complications in pregnancy   Reproduction, fertility and contraception   Thrombosis and haemostasis   Vascular Biology, Thrombosis
Project Title
 Thrombomodulin as a predictor for chemotherapy associated venous thromboembolism
From
January 2023
To
January 2024
Summary
Funding Agency
TCD faculty of Health Sciences Dean's Research initiative
Programme
Dean's Research Initiative
Project Title
 Activated protein C pathway in ovarian cancer -a novel prognostic marker?
From
Dec 2021
To
Dec 2022
Summary
Development of preliminary findings investigating the role of aPC pathway in the aetiology of ovarian cancer
Funding Agency
TCD
Programme
Research Boost Programme
Project Title
 PINPOINT: PredIction aNd Prevention Of Venous Thrombosis durINg chemoTherapy- combining dynamic biomarker risk assessment, patient perspectives and health technology assessment.
From
01.10.2024
To
01.10.2028
Summary
Venous thromboembolism(VTE) is the leading cause of non cancer death in cancer patients. Patients are particularly at risk during chemotherapy where rates of up to 20% have been reported. Guidelines recommend primary prophylaxis with direct oral anticoagulants(DOACs) in intermediate/high risk patients undergoing chemotherapy following risk assessment with a validated risk score(Khorana score). However, the Khorana score performs poorly in lung, ovarian and gastric cancers and relies on a single assessment at the start of therapy. The development of VTE is a dynamic process which cannot be accurately represented by a single risk assessment. Our data suggests that markers of procoagulant activity are implicated in chemotherapy associated VTE and could be measured serially as predictive biomarkers. This may provide a more effective method of identifying patients at risk of VTE and facilitate targeted prophylaxis. Prophylaxis with DOACs carries a risk of bleeding hence decisions regarding prophylaxis should be shared between doctor and patient. However, studies have shown that cancer patients receive limited information about VTE risk and tools to aid decision making in this area are lacking. Cost is also a consideration for both the health service and the patient. In this study we will: " measure procoagulant biomarker levels serially during chemotherapy as dynamic predictors of VTE. " investigate the prothrombotic mechanisms involved in chemotherapy associated VTE. " identify patient needs and priorities for shared decision making with regard to prophylaxis during chemotherapy " perform a cost benefit analysis of biomarker screening and targeted VTE prophylaxis during chemotherapy This study aims is to develop dynamic predictive biomarkers for VTE during chemotherapy and to understand patient priorities with regard to VTE prevention during chemotherapy. Identification of high risk patients and increased understanding or patient priorities and costs will lead to effective shared decision between doctor and patient ultimately reducing the burden of VTE in cancer.
Funding Agency
HRB
Programme
ILP
Project Type
Investigator Led Research project
Project Title
 THE ROLE OF TISSUE FACTOR IN THE TRANSITION FROM ENDOMETRIOSIS TO CLEAR CELL CANCER OF THE OVARY
From
2014
To
2016
Summary
Increased expression of both PAR-2 and TF in the eutopic and ectopic endometrium from women with endometriosis compared with normal women has been reported (Krikun et al,2008) however it is unknown whether a further increase in expression is implicated in malignant transformation of endometrioma into clear cell cancer. Our hypothesis is that expression and activation of the TF-VIIa-PAR-2 signalling pathway is further increased in clear cell cancers particularly those formed on a background of endometriosis and that this may provide a potential target for treatment of clear cell cancers. We also believe that TFPI-2 may be a useful diagnostic marker for clear cell cancers. The aim of the study is to compare the expression of TF, VIIa and PAR-2 in clear cell cancers with endometrial tissue from patients with endometriosis. A secondary aim is to investigate the role of serum TFPI-2 as a possible non invasive tool for distinguishing endometriosis from clear cell cancers.
Funding Agency
Leo pharma
Programme
Unrestricted educational grant
Project Type
[Co-applicant with Dr Noreen Gleeson]
Person Months
24
Project Title
 Thromboelastography as a predictor of venous thrombosis in gynaecological oncology patients undergoing surgery.
From
2012
To
2015
Summary
Ovarian cancer is associated with high rates of venous thromboembolism (VTE) particularly after surgery even in the setting of appropriate prophylaxis.The treatment and prevention of VTE is challenging in these patients after major surgery, as pelvic surgery itself is also an additional high risk factor for VTE. Thromboelastography(TEG) is a technique which allows rapid global assessment of haemostatic/fibrinolytic function and has been proposed as a marker of hypercoagulability in a variety of clinical settings. The aim of this study is to determine the level of hypercoagulability using TEG in patients undergoing major gynaecological surgery for suspected cancer, and to determine the potential of TEG as a predictor of VTE.
Funding Agency
Gynaecological Cancer Fund, SJH
Project Type
[Co-applicant with Dr Noreen Gleeson]

Page 1 of 3
Details Date
Co-Editor in Chief of Thrombosis Update 2019
Member of the Editorial board of Thrombosis Research
Member of International Society for Thrombosis and Haemostasis publications committee 2016-2020
Member Editorial Board European Journal of Gynaecological Oncology 2021
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
Details Date From Date To
Member of International Society for Thrombosis and Haemostasis 2010 2020
Irish Society for Gynaecological Oncology 2016-present
Irish Association of Cancer Research 2015-present
Irish National Network for Ovarian Cancer Collaboration INNOVATION Founder member 2016 Present
Norris, Lucy A. and Papadakis, Emmanouil S., Multimorbidity and VTE, Thrombosis Update, 18, 2025, Notes: [Cited by: 0; All Open Access, Gold Open Access], Journal Article, PUBLISHED  DOI
Papadakis, Emmanouil S. and Norris, Lucy A., Optimizing end of life care in cancer Patients. Focus on antithrombotic treatment, Thrombosis Update, 19, 2025, Notes: [Cited by: 0], Journal Article, PUBLISHED  DOI
LEWIS, F., WARD, M. P., SAADEH, F. A., O'GORMAN, C., MAGUIRE, P. J., BEIRNE, J. P., KAMRAN, W., IBRAHIM, E., NORRIS, L., KELLY, T., HURLEY, S., HENDERSON, B., KANJUGA, M., O'DRISCOLL, L., GATELY, K., ONER, E., SAINI, V. M., CADOO, K., MARTIN, C., O'LEARY, J. J. & O'TOOLE, S. A., A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas, European Journal of Surgical Oncology, 2025, Journal Article, PUBLISHED
Batog WI, Norris L, O'Toole S, Maguire P, O'Gorman C, Kelly M, Saadeh FA., Identification of groin node metastasis in squamous cell vulval cancer using preoperative [<sup>18</sup>F] FDG-PET/CT. Can unnecessary lymphadenectomy be prevented?, European journal of obstetrics, gynecology, and reproductive biology, 310, 2025, p113959 , Journal Article, PUBLISHED  DOI
Ward MP, Ibrahim EM, O'Toole SA, Marchocki Z, O'Leary JJ, Saadeh FA, Norris LA., Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis., Thrombosis research, 246, 2024, p109251 , Journal Article, PUBLISHED  DOI
Papadakis, Emmanouil S. and Norris, Lucy A., Breaking the barriers to VTE prevention in ambulatory cancer patients: When implementation strategy comes into play, Thrombosis Update, 15, 2024, Notes: [Cited by: 0; All Open Access, Gold Open Access], Journal Article, PUBLISHED  DOI
LEWIS, F., BEIRNE, J., HENDERSON, B., NORRIS, L., CADOO, K., KELLY, T., MARTIN, C., HURLEY, S., KANJUGA, M., O'DRISCOLL, L., GATELY, K., ONER, E., SAINI, V. M., BROOKS, D., SELEMIDIS, S., KAMRAN, W., HAUGHEY, N., MAGUIRE, P., O'GORMAN, C., SAADEH, F. A., WARD, M. P., O'LEARY, J. J. & O'TOOLE, S. A., Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma, Cancer Letters, 2024, Journal Article, PUBLISHED
Norris, Lucy A. and Papadakis, Emmanouil S., Nitrous oxide and VTE â€" no laughing matter, Thrombosis Update, 16, 2024, Notes: [Cited by: 0; All Open Access, Gold Open Access], Journal Article, PUBLISHED  DOI
Norris, Lucy A. and Papadakis, Emmanouil S., How reliable are ICD codes for venous thromboembolism?, Thrombosis Update, 14, 2024, Notes: [Cited by: 0; All Open Access, Gold Open Access], Journal Article, PUBLISHED  DOI
Papadakis, Emmanouil S. and Norris, Lucy A., Improving management of catheter related thrombosis (CRT) in cancer patients by incorporating real world data. The value of cancer VTE registries, Thrombosis Update, 17, 2024, Notes: [Cited by: 0; All Open Access, Gold Open Access], Journal Article, PUBLISHED  DOI
  

Page 1 of 13
Kearns, P; McCullagh L; Norris L; McConnell D, Evaluating The Cost-Effectiveness of Repeated Serological Biomarker Screening Compared to the Khorana Risk Score for Guiding Thromboprophylaxis Prescription in Patients Receiving Chemotherapy, SPHeRE Network 11th Annual Conference: Translating Research to Health Policy and System Change, Royal College of Surgeons Ireland, Dublin, 04 March 2025, 2025, Oral Presentation, PRESENTED
Norris Lucy A, Biomarkers for cancer associated venous thromboembolism, Hospital Professional News, 2023, Notes: [https://hospitalprofessionalnews.ie/2023/02/14/biomarkers-for-cancer-associated-venous-thromboembolism/], Review Article, PUBLISHED
Lucy Norris, Can we predict VTE in gynaecological cancer?, Irish Society for Gynae-Oncology (ISGO) annual scientific meeting 'TRANSLATION AND INNOVATION'., Dublin, December 1st , 2016, ISGO, Invited Talk, PRESENTED
Lucy Norris, Prediction and Prevention of venous thromboembolism in Gynaecological cancer. , Master class in Cancer and Thrombosis, Dublin, July 7, 2015, 87-, Invited Talk, PRESENTED
Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, Published Abstract, PUBLISHED
Lucy Norris, HRT and haemostasis, UCC Obstetrics and Gynaecology, research seminar, Cork, February, 2011, UCC, 87-, Invited Talk, PRESENTED
Abu Saadeh F, Norris L, O'Toole S, Gleeson N. , The role of tissue factor and tissue factor pathway inhibitor in ovarian cancer, Thrombosis Research, Womens Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl 3), Elsevier, 2011, pp149 - 149, Meeting Abstract, PUBLISHED
SK Ismail, Norris LA, Muttukrishna S, Higgins JR, Effect of LMWH prophylaxis on thrombin generation post caesarean section, Thrombosis Research, Women's Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl), 2011, ppS137 - S137, Meeting Abstract, PUBLISHED
Lynne Kelly, Shanthi Muttukrishna, Lucy Norris, John Higgins, Placental expression of haemostatic and angiogenic markers in preeclampsia, Hydrometallurgy, 1, (3), 2011, pp277-, Published Abstract, PUBLISHED
Lucy Norris, Hormones and the risk of thrombosis., Update on Coagulation, Dublin, March, 2010, National Centre for Coagulation and Hereditary disorders, 87-, Invited Talk, PRESENTED

  


Page 1 of 2
The role of coagulation proteases and platelets in the aetiology of gynaecological cancers. Development of risk models for the prediction of thrombosis in gynaecological cancer patients. The effect of chemotherapy in natural anticoagulant pathways. Aetiology of thrombosis risk in high risk pregnancy patients. Effects of oestrogens, progestogens and phytoestogens on coagulation gene expression and their role in thrombosis risk. The role of coagulation gene expression in the transition from endometriosis to clear cell cancer.